Spyre Therapeutics Profit Margin

Spyre Therapeutics's profit margin stands at -197.71% as of June 2026. That is below the Healthcare sector average of 14.34%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Spyre Therapeutics sits lower the Healthcare benchmark (14.34%) with a profit margin of -197.71%. That is roughly 1478.3% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -197.71% for Spyre Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Spyre Therapeutics's profit margin evolved across reporting periods, while the comparison chart places SYRE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, profit margin is commonly used to spot outliers. Spyre Therapeutics's reading of -197.71% (sector avg 14.34%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.